Related Experiment Video

Updated: May 28, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Inflammatory markers in coronary heart disease

Mohammad Madjid1, James T Willerson

  • 1Texas Heart Institute, Houston, TX, USA.

British Medical Bulletin
|October 20, 2011
PubMed

Insights

Inflammation markers like C-reactive protein (CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) indicate increased coronary heart disease (CHD) risk. Statins may reduce CHD risk in individuals with elevated CRP, even without high cholesterol.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Biomarker Discovery

Background:

  • Inflammation is a critical factor in atherosclerosis and coronary heart disease (CHD) development.
  • Understanding inflammatory markers aids in assessing cardiovascular risk.

Purpose of the Study:

  • To review the role of C-reactive protein (CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) in predicting CHD risk.
  • To evaluate the clinical utility of inflammatory markers in cardiovascular risk stratification.

Main Methods:

  • Systematic review of peer-reviewed, English-language studies.
  • Focus on studies investigating CRP and Lp-PLA2 in relation to CHD events.

Main Results:

  • Elevated serum CRP and Lp-PLA2 levels are linked to higher risk of incident CHD events.
  • These markers are associated with risk across diverse populations and in primary/secondary prevention.
  • Inflammatory markers are most beneficial for risk prediction in intermediate-risk individuals.

Conclusions:

  • Statin therapy can decrease CHD risk in patients with elevated CRP, even in the absence of hyperlipidemia.
  • Ongoing research aims to identify more specific serum markers for coronary artery inflammation.
  • Targeting vascular inflammation with specific inhibitors, alongside statins, shows promise for future cardiovascular event prevention.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...